The American Society of Tropical Medicine and Hygiene has waived the Open Access fee for this article due to the ongoing COVID-19 pandemic.
Kara L et al., 2021. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin Infect Dis 72: 301–308.
Ging F et al.2020. Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. J Clin Invest 130: 6588–6599.
Grifoni A et al.2020. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181: 1489–1501.e15.
Kroemer M et al.2021. COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity. J Infect 82: 282–327.
Le Bert N et al.2020. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584: 457–462.
Ni L et al.2020. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52: 971–977.e3.
Sattler A, Angermair S, Stockmann H, Heim KM, Khadzhynov D, Treskatsch S, Halleck F, Kreis ME, Kotsch K , 2020. SARS-CoV-2 specific T-cell responses and correlations with COVID-19 patient predisposition. J Clin Invest 130: 6477–6489.
Sekine T et al.2020. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 193: 158–168.e14.
Weiskopf D et al.2020. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol 5: eabd2071.
Classen DC, Morningstar JM, Shanley JD , 1987. Detection of antibody to murine cytomegalovirus by enzyme-linked immunosorbent and indirect immunofluorescence assays. J Clin Microbiol 25: 600–604.
Lardeux F, Torrico G, Aliaga C , 2016. Calculation of the ELISA’s cut-off based on the change-point analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence of controls. Mem Inst Oswaldo Cruz Rio de Janeiro 111: 501–504.
Kim JY et al.2018. Combined IFN- γ and TNF-α release assay for differentiating active tuberculosis from latent tuberculosis infection. J Infect 77: 314–320.
Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, Zhu Q, Liu L , 2020. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71: 2255–2258.
Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC , 2004. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect 10: 1062–1066.
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, Ferbas KG, Tobin NH, Aldrovandi GM, Yang OO , 2020. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. N Engl J Med 383: 1085–1087.
Kim YS et al.2020. Sustained responses of neutralizing antibodies against MERS-CoV in recovered patients and their therapeutic applicability. Clin Infect Dis Sep 8: ciaa1345 (Epub ahead of print).
Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, Zheng L, Lan T, Wang LF, Liang GD , 2007. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis 13: 1562–1564.
Altmann DM, Boyton RJ , 2020. SARS-CoV-2 T cell immunity: specificity, function, durability, and role in protection. Sci Immunol 5: eabd6160.